From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Ratain
Mark J
MJ
Section of Hematology/Oncology, Department of Medicine, Committees on Clinical Pharmacology and Pharmacogenomics and Molecular Medicine, and Cancer Research Center, The University of Chicago, Chicago, Illinois 60637, USA. mratain@medicine.bsd.uchicago.edu
D000972:Antineoplastic Agents, Phytogenic / Q000378:metabolism / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D000077146:Irinotecan; D010597:Pharmacogenetics / Q000379:methods / Q000639:trends; D011110:Polymorphism, Genetic; D018581:Technology Transfer; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D000099148:UGT1A1 Enzyme
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D000099148:UGT1A1 Enzyme